Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it continues to advance its sales and marketing programs and is preparing to launch its first product, SmoothX barium sulfate CT contract media oral suspension for the CT imaging market, in Canada.
The company also announced that Ethan Mohan has joined its sales team as Canadian Sales Manager.
Mohan will be responsible for executing the company’s sales program and has already begun meeting with Government Health Service agencies and private clinics across Canada.
READ: Voyageur Pharmaceuticals completes second and final closing of its private placement for gross proceeds of $1,019,953.53
Voyageur CEO Brent Willis said from the start of the development of its barium contrast media products, Voyageur has been committed to supporting the imaging market with high-quality products that address the needs of patients and physicians alike.
“To this end, we are working closely with our Scientific Advisory Board to develop scientific and practical base materials that will support our customer-oriented sales programs," he said.
Further, Voyageur noted that it continues to advance the application for the United States Food and Drug Administration (FDA) approval to market barium contrast products in the United States.
The company noted that in accordance with a February 8, 2023, letter that it received from the FDA, barium sulfate products will continue to be regulated as drugs in the US market.
In anticipation of this recent decision by the FDA, Voyganeur said it has established all its product protocols, procedures, and testing standards in accordance with FDA regulations and guidelines that apply to drugs.
The company noted that, based on these actions, it continues to advance the development and testing of four additional imaging products and is moving forward positively as it relates to its first product application for approval from the FDA in a timely manner.
Voyageur is focused on the development of barium and iodine Active Pharmaceutical Ingredients and high-performance, cost-effective imaging contrast agents for the medical imaging marketplace.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie